###begin article-title 0
###xml 28 32 28 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CNR1</italic>
The Cannabinoid 1 Receptor (CNR1) 1359 G/A Polymorphism Modulates Susceptibility to Ulcerative Colitis and the Phenotype in Crohn's Disease
###end article-title 0
###begin p 1
Conceived and designed the experiments: MS JD TO BG PL SB. Performed the experiments: DE. Analyzed the data: MS DE JD SP PL SB. Contributed reagents/materials/analysis tools: MS TO BG PL. Wrote the paper: MS SB.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 191 195 191 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CNR1</italic>
###xml 310 318 <span type="species:ncbi:9606">patients</span>
Recent evidence suggests a crucial role of the endocannabinoid system, including the cannabinoid 1 receptor (CNR1), in intestinal inflammation. We therefore investigated the influence of the CNR1 1359 G/A (p.Thr453Thr; rs1049353) single nucleotide polymorphism (SNP) on disease susceptibility and phenotype in patients with ulcerative colitis (UC) and Crohn's disease (CD).
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 88 92 88 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CNR1</italic>
###xml 130 138 <span type="species:ncbi:9606">patients</span>
###xml 152 160 <span type="species:ncbi:9606">patients</span>
Genomic DNA from 579 phenotypically well-characterized individuals was analyzed for the CNR1 1359 G/A SNP. Amongst these were 166 patients with UC, 216 patients with CD, and 197 healthy controls.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 62 66 62 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CNR1</italic>
###xml 423 425 423 425 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;7</sup>
Compared to healthy controls, subjects A/A homozygous for the CNR1 1359 G/A SNP had a reduced risk to develop UC (p = 0.01, OR 0.30, 95% CI 0.12-0.78). The polymorphism did not modulate CD susceptibility, but carriers of the minor A allele had a lower body mass index than G/G wildtype carriers (p = 0.0005). In addition, homozygous carriers of the G allele were more likely to develop CD before 40 years of age (p = 5.9x10-7) than carriers of the A allele.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 7 8 7 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</italic>
The CNR1 p.Thr453Thr polymorphism appears to modulate UC susceptibility and the CD phenotype. The endocannabinoid system may influence the manifestation of inflammatory bowel diseases, suggesting endocannabinoids as potential target for future therapies.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 194 197 194 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009453-Grinspoon1">[1]</xref>
###xml 199 202 199 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009453-Grinspoon2">[2]</xref>
###xml 330 331 330 331 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 598 601 598 601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009453-Massa1">[3]</xref>
###xml 602 605 602 605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009453-Storr1">[7]</xref>
###xml 651 652 651 652 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 688 689 688 689 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 701 705 701 705 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CNR1</italic>
###xml 705 708 705 708 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 767 770 767 770 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009453-Massa1">[3]</xref>
###xml 772 775 772 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009453-Storr1">[7]</xref>
###xml 825 826 825 826 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 1020 1021 1020 1021 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 1090 1093 1090 1093 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009453-DArgenio1">[4]</xref>
###xml 31 40 <span type="species:ncbi:3483">marijuana</span>
###xml 130 138 <span type="species:ncbi:9606">patients</span>
###xml 422 428 <span type="species:ncbi:10090">murine</span>
###xml 709 713 <span type="species:ncbi:10090">mice</span>
###xml 980 986 <span type="species:ncbi:9606">humans</span>
Anecdotal reports suggest that marijuana- or tetrahydrocannabinol-containing products may be effective in alleviating symptoms in patients with ulcerative colitis (UC) and Crohn's disease (CD). [1], [2] This is supported by recent studies of our group and others suggesting that pharmacological activation of the cannabinoid 1 (CB1) receptor with selective receptor agonists decreases the inflammatory response in various murine models of colonic inflammation including dinitrobenzene sulphonic acid (DNBS)-, trinitrobenzene sulphonic acid (TNBS)- and dextran sodium sulfate (DSS)-induced colitis. [3]-[7] Interestingly, pharmacological blockade of CB1 receptors or genetic ablation of CB1 receptors (CNR1-/- mice) aggravates intestinal inflammation in these models, [3], [7] emphasizing the physiological relevance of the CB1 receptor in the protection against intestinal inflammation. Increased mucosal levels of the endocannabinoid anandamide during intestinal inflammation in humans further stress the role of the CB1 receptor and the endocannabinoid system in intestinal inflammation. [4] Thus, present knowledge suggests up-regulation of endocannabinoids as an important protective mechanism in intestinal inflammation.
###end p 11
###begin p 12
###xml 37 38 37 38 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 45 46 45 46 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 223 226 223 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009453-Hiley1">[8]</xref>
###xml 247 250 247 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009453-Caraceni1">[9]</xref>
###xml 277 281 277 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009453-Sarzani1">[10]</xref>
###xml 283 287 283 287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009453-Scheen1">[11]</xref>
###xml 339 343 339 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009453-Idris1">[12]</xref>
###xml 447 451 447 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009453-Maresz1">[13]</xref>
###xml 453 457 453 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009453-TeixeiraClerc1">[14]</xref>
###xml 689 692 689 692 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009453-Massa1">[3]</xref>
###xml 694 698 694 698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009453-DePetrocellis1">[15]</xref>
###xml 699 703 699 703 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009453-Izzo2">[20]</xref>
###xml 804 805 804 805 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 852 855 852 855 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009453-Massa1">[3]</xref>
The endocannabinoid system and the CB1 and CB2 receptors seem to be crucially involved in the regulation of multiple physiological functions, e.g. in the heart, where they relax coronary arteries and decrease cardiac work, [8] in organ perfusion, [9] in metabolic homeostasis, [10], [11] and in the regulation of bone mass by osteoclasts, [12] as well as in the protection against stress responses, inflammation, and associated repair mechanisms. [13], [14] Although recent evidence suggests that the endocannabinoid system is involved in many physiological and pathophysiological functions of the gastrointestinal tract such as intestinal motility, secretion, and intestinal inflammation [3], [15]-[20], the exact mechanisms underlying these findings are not yet known. It was recently suggested that CB1 signaling may be up-regulated during colitis, [3] but it is unknown whether this is a specific feature of the colitis model or a general response to intestinal inflammation.
###end p 12
###begin p 13
###xml 28 29 28 29 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 237 240 237 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009453-DArgenio1">[4]</xref>
###xml 347 350 347 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009453-DArgenio1">[4]</xref>
###xml 42 47 <span type="species:ncbi:9606">human</span>
###xml 172 180 <span type="species:ncbi:9606">patients</span>
###xml 472 477 <span type="species:ncbi:9606">human</span>
Moreover, the role of the CB1 receptor in human inflammatory bowel disease (IBD) has not been clarified. Increased anandamide levels were found in mucosal biopsies from UC patients, suggesting a role of the endocannabinoid system in UC. [4] In contrast, the colonic expression of the endocannabinoid 2-acyl-glycerol (2-AG) is not increased in UC. [4] So far, however, no other studies analyzing the endocannabinoid system or the pharmacological effects of cannabinoids in human IBD have been published.
###end p 13
###begin p 14
###xml 285 289 285 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009453-Mayer1">[21]</xref>
###xml 291 295 291 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009453-Barbara1">[22]</xref>
###xml 357 361 357 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009453-Barrett1">[23]</xref>
Gastrointestinal inflammation is likely the result of multiple factors, e.g., increased pro-inflammatory stimuli and reduced protective capability. The overall balance between pro- and anti-inflammatory mechanisms may determine the progression and severity of intestinal inflammation. [21], [22] Given the results of recent genome-wide association studies, [23] genetic susceptibility is an important factor contributing to IBD development. Moreover, knowledge of genetic susceptibility factors could provide important pathophysiologic insights for the generation of novel IBD therapeutics.
###end p 14
###begin p 15
###xml 95 98 95 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009453-Massa1">[3]</xref>
###xml 100 103 100 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009453-Sibaev1">[6]</xref>
###xml 105 108 105 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009453-Storr1">[7]</xref>
###xml 110 114 110 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009453-Storr4">[24]</xref>
###xml 160 164 160 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CNR1</italic>
###xml 192 193 192 193 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 483 487 483 487 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CNR1</italic>
###xml 508 509 508 509 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 621 625 621 625 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CNR1</italic>
###xml 835 839 835 839 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009453-Schmidt1">[25]</xref>
###xml 841 845 841 845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009453-Ujike1">[26]</xref>
###xml 63 69 <span type="species:ncbi:10090">murine</span>
###xml 367 375 <span type="species:ncbi:9606">patients</span>
Considering our previous work on the endocannabinoid system in murine intestinal inflammation, [3], [6], [7], [24] we hypothesized that genetic variants in the CNR1 gene, which may modulate CB1 receptor function, could be associated with an increased susceptibility to IBD. To test our hypothesis, we genotyped a cohort of more than 550 individuals including 382 IBD patients and analyzed whether the 1359 G/A (p.Thr453Thr; rs1049353) single nucleotide polymorphism (SNP) within the CNR1 gene encoding the CB1 receptor modulates the susceptibility to CD and UC or results in a certain IBD phenotype. The selection of the CNR1 1359 G/A SNP was based on previous studies reporting that this polymorphism is associated with other disorders modulated by the endocannabinoid system such as alcohol dependence and hebephrenic schizophrenia. [25], [26]
###end p 15
###begin title 16
Methods
###end title 16
###begin title 17
Ethics Statement
###end title 17
###begin p 18
The study was approved by the Ethics Committee of the Medical Faculty of the University of Munich. All participating subjects gave their written, informed consent prior to the genetic analysis.
###end p 18
###begin title 19
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human Study Population
###end title 19
###begin p 20
###xml 425 432 425 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0009453-t001">Table 1</xref>
###xml 1143 1147 1143 1147 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CNR1</italic>
###xml 1297 1301 1297 1301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009453-Gasche1">[27]</xref>
###xml 1373 1377 1373 1377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009453-Silverberg1">[28]</xref>
###xml 62 70 <span type="species:ncbi:9606">patients</span>
###xml 130 138 <span type="species:ncbi:9606">Patients</span>
###xml 1158 1166 <span type="species:ncbi:9606">Patients</span>
The study population comprised 579 individuals, including 216 patients with CD, 166 with UC, and 197 healthy, unrelated controls. Patients and controls were recruited at the IBD center of the Ludwig-Maximilians-University Munich, Campus Grosshadern, from September 2002 to December 2006. The diagnoses of CD and UC were established following clinical guidelines, using endoscopic, radiological, and histopathologic criteria. Table 1 shows the baseline characteristics of the study population. All 197 controls were unrelated, healthy individuals of Caucasian origin and sex-matched (by frequency) to the CD group. Controls were healthy blood donors without a history or family history of IBD. Demographics and routine clinical data (including location and behavior of IBD, disease-related complications, and prescription data of immunosuppressive and immunomodulatory therapy e.g., azathioprine, 6-mercaptopurine, methotrexate, infliximab) were recorded by retrospective analysis of the clinical charts by two independent investigators and an interview including a questionnaire at the time of enrollment. All data were collected blind to the CNR1 genotype. Patients with CD or UC were grouped according to age at diagnosis, disease localization, and behavior status of the Vienna classification, [27] and the recent modifications suggested by the Montreal classification. [28]
###end p 20
###begin title 21
Demographic characteristics of the study population.
###end title 21
###begin title 22
DNA Extraction and Genotyping of the CNR1 Polymorphism
###end title 22
###begin p 23
###xml 101 105 101 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CNR1</italic>
###xml 123 127 123 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009453-Schmidt1">[25]</xref>
###xml 129 133 129 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009453-Gadzicki1">[29]</xref>
###xml 369 372 369 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009453-Storr1">[7]</xref>
###xml 374 378 374 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009453-Storr5">[30]</xref>
###xml 532 558 528 554 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GAAAGCTGCATCAAGAGCCC-3&#8242;</named-content>
###xml 573 598 569 594 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-TTTTCCTGTGCTGCCAGGG-3&#8242;</named-content>
###xml 655 656 651 652 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Recently, a guanosine-to-adenine substitution at nucleotide position 1359 has been identified in the CNR1 gene (rs1049353) [25], [29]. Thus, three genotypes (GG, GA, AA) are possible. Genomic DNA was isolated from peripheral blood leukocytes by standard procedures using the DNA blood mini kit from Qiagen (Hilden, Germany). Genotyping was done as previously described [7], [30]. Briefly, a single 20-microl PCR was performed to genotype this site using approximately 200 ng of genomic DNA and 20 pmol each of the following primers 5'-GAAAGCTGCATCAAGAGCCC-3' (forward) and 5'-TTTTCCTGTGCTGCCAGGG-3' (reverse). Other conditions were as follows: 1.5 mM MgCl2, 400 microM of each dNTP, 1.25 U Taq polymerase, and 1x reaction buffer (Life Technologies, Rockville, MD). DNA amplification was performed with 40 cycles of 94degreesC, 60degreesC, and 72degreesC for 30 seconds each, preceded by a single cycle of 95degreesC for 15 minutes and followed by a single cycle of 72degreesC for 5 minutes. Five microl of the resulting 111 bp PCR product were then digested overnight with 10 U of Mspl (New England Biolabs, Beverly, MA) at 37degreesC. This resulted in fragments of 92 and 19 bp, when a G was present at nucleotide position 385, while the fragment remained uncut, when an A was present. Restriction digests were analyzed by electrophoresis of the digestion mixture in a 2% agarose gel stained with ethidium bromide. The assay was verified by sequencing the PCR product and the digested PCR fragments of all possible genotypes.
###end p 23
###begin title 24
Statistics
###end title 24
###begin p 25
Fisher's exact test was used for comparison between categorical variables. All tests were two-tailed. P values <0.05 were considered as significant. Analyses were performed using SPSS 14.0.1 software for Windows.
###end p 25
###begin title 26
Results
###end title 26
###begin title 27
The CNR1 1359 G/A (p.Thr453Thr) Polymorphism Modulates UC but Not CD Susceptibility
###end title 27
###begin p 28
###xml 37 38 37 38 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 141 145 141 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CNR1</italic>
###xml 211 215 211 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009453-Schmidt1">[25]</xref>
###xml 217 221 217 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009453-Horne1">[31]</xref>
###xml 405 412 405 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0009453-t001">Table 1</xref>
###xml 598 602 598 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009453-Gasche1">[27]</xref>
###xml 604 608 604 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009453-Silverberg1">[28]</xref>
###xml 421 429 <span type="species:ncbi:9606">patients</span>
###xml 625 633 <span type="species:ncbi:9606">patients</span>
###xml 811 819 <span type="species:ncbi:9606">patients</span>
###xml 840 848 <span type="species:ncbi:9606">patients</span>
Given the above reported increased CB1 receptor expression in several models of intestinal inflammation and previous studies implicating the CNR1 1359 G/A (p.Thr453Thr) SNP in endocannabinoid-mediated diseases, [25], [31] we investigated whether this polymorphism modulates susceptibility and phenotype of CD and UC. The demographic characteristics of the IBD and control population analyzed are given in Table 1. The CD patients were classified with regard to their disease phenotype, considering disease location, the age at diagnosis, and disease behaviour by using the Montreal classification. [27], [28] The majority of patients had an onset of the disease in their mid20s (mean age at first diagnosis of CD: 28.1+/-11.4 years). The mean age at first diagnosis of UC was 31.8+/-13.7 years. 13.9% of the CD patients and 12.7% of the UC patients had a positive family history of IBD.
###end p 28
###begin p 29
###xml 123 130 123 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0009453-t002">Table 2</xref>
###xml 469 476 469 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0009453-t002">Table 2</xref>
###xml 66 74 <span type="species:ncbi:9606">patients</span>
###xml 83 91 <span type="species:ncbi:9606">patients</span>
###xml 299 307 <span type="species:ncbi:9606">Patients</span>
The results of the CNR1 p.Thr453Thr genotyping analysis in 216 CD patients, 166 UC patients, and 197 controls are shown in Table 2. The frequencies of heterozygous and homozygous carriers of this polymorphism did not differ significantly from the expected ratio according to the Hardy-Weinberg law. Patients with UC were less likely to be 1359 A/A homozygous (p = 0.01, OR 0.30, 95% CI 0.12-0.78). In contrast, this polymorphism did not influence susceptibility to CD (Table 2).
###end p 29
###begin title 30
###xml 24 28 24 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CNR1</italic>
###xml 68 76 <span type="species:ncbi:9606">patients</span>
Genotype frequencies of CNR1 1359 G/A (p.Thr453Thr) polymorphism in patients with Crohn's disease (CD) and ulcerative colitis (UC) as well as in controls.
###end title 30
###begin title 31
The CNR1 1359 G/A (p.Thr453Thr) Polymorphism Modulates Disease Onset and Body Mass Index in CD
###end title 31
###begin p 32
###xml 3 10 3 10 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0009453-t003">Table 3</xref>
###xml 69 73 69 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CNR1</italic>
###xml 320 322 320 322 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;7</sup>
###xml 550 557 550 557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0009453-t003">Table 3</xref>
###xml 643 650 643 650 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0009453-t004">Table 4</xref>
###xml 102 110 <span type="species:ncbi:9606">patients</span>
In Table 3, we provide a detailed genotype-phenotype analysis of the CNR1 1359 G/A polymorphism in CD patients. Carriers of the 1359 A/A genotype were likely to have a lower body weight (p = 0.0005). In addition, homozygous carriers of the major G allele were more likely to develop CD before 40 years of age (p = 5.9x10-7) than carriers of the minor A allele. There was no association between the CNR1 p.Thr453Thr polymorphism and disease location, use of immunosuppressive drugs, family history of IBD, CD-related surgery, stenoses, and abscesses (Table 3). In addition, the CNR1 p.Thr453Thr polymorphism did not influence the UC phenotype (Table 4).
###end p 32
###begin title 33
###xml 24 28 24 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CNR1</italic>
Association between the CNR1 1359 G/A (p.Thr453Thr) genotype and CD characteristics.
###end title 33
###begin p 34
###xml 70 74 70 74 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009453-Silverberg1">[28]</xref>
Disease behavior was defined according to the Montreal classification [28]. A stricturing disease phenotype was defined as presence of stenosis without penetrating disease. The diagnosis of stenosis was made surgically, endoscopically, or radiologically (using MRI enteroclysis).
###end p 34
###begin p 35
Immunosuppressive agents included azathioprine, 6-mercaptopurine, 6-thioguanin, methotrexate, and/or infliximab.
###end p 35
###begin p 36
Extraintestinal manifestations were defined as one or more of the following IBD-related diseases: non-medication-induced arthropathies (e.g., ankylosing spondylitis, sacroileitis, peripheral arthritis), eye involvement (e.g., episcleritis and/or iritis/uveitis), skin involvement (e.g., erythema nodosum and pyoderma gangrenosum), non-medication-induced biliary disease (e.g., sclerosing cholangitis).
###end p 36
###begin p 37
Only surgery related to CD-specific problems (e.g., fistulectomy, colectomy, ileostomy) was included.
###end p 37
###begin title 38
###xml 20 24 20 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CNR1</italic>
Association between CNR1 1359 G/A (p.Thr453Thr) genotype and UC disease characteristics.
###end title 38
###begin p 39
Immunosuppressive agents included azathioprine, 6-mercaptopurine, and/or infliximab.
###end p 39
###begin p 40
Only UC-related surgery (e.g., colectomy) was included.
###end p 40
###begin p 41
Extraintestinal manifestations were defined as one or more of the following IBD-related diseases: non-medication-induced arthropathies (e.g., ankylosing spondylitis, sacroileitis, peripheral arthritis), eye involvement (e.g., episcleritis and iritis/uveitis), skin involvement (e.g., erythema nodosum and pyoderma gangrenosum), non-medication-induced biliary disease (e.g., sclerosing cholangitis).
###end p 41
###begin title 42
Discussion
###end title 42
###begin p 43
###xml 173 174 173 174 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 291 294 291 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009453-Massa1">[3]</xref>
###xml 296 299 296 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009453-Storr1">[7]</xref>
###xml 361 362 361 362 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 531 535 531 535 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CNR1</italic>
###xml 556 557 556 557 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 692 696 692 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009453-Schmidt1">[25]</xref>
###xml 715 719 715 719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009453-Leroy1">[32]</xref>
###xml 899 903 899 903 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009453-Komar1">[33]</xref>
We analyzed the effect of the CNR1 p.Thr453Thr polymorphism on IBD susceptibility and disease phenotype. This study was based on our previous results which suggested that CB1 receptor signaling is involved in defense mechanisms in response to acute intestinal inflammation in animal models. [3], [7] Based on this knowledge, we hypothesized that differential CB1 receptor expression, e.g., modulated by genetic factors, may contribute to IBD susceptibility. In the present study, we focused on the 1359 G/A polymorphism within the CNR1 gene encoding the CB1 receptor, given the importance of this nucleotide substitution in other endocannabinoid-mediated disorders such as alcohol dependence [25] and schizophrenia [32]. Although the CNR1 1359 G/A (p.Thr453Thr) SNP is a silent mutation, which does not result in an amino acid exchange, it might be associated with alterations e.g. in RNA splicing. [33]
###end p 43
###begin p 44
###xml 404 408 404 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009453-Gadzicki1">[29]</xref>
###xml 188 196 <span type="species:ncbi:9606">patients</span>
###xml 218 226 <span type="species:ncbi:9606">patients</span>
###xml 529 537 <span type="species:ncbi:9606">patients</span>
Our study demonstrated an association with UC susceptibility but not with CD susceptibility. The prevalence of 1359 A/A homozygous carriers was 10.7% in the control population, 6.9% in CD patients, and only 3.6% in UC patients. The genotype frequencies found for our control population were within the values expected from Hardy-Weinberg equilibrium and were similar to a previous German control cohort. [29] However, given the limited size of the study population and the low prevalence of 1359 A/A homozygous carriers among UC patients, this finding has to be confirmed in larger replication cohorts. Furthermore, given that the study was primarily designed to detect differences in the frequency of IBD risk alleles, the control population was selected only regarding absence of IBD and other chronic diseases as well as being negative for a family history of IBD. Therefore a selection bias resulting in differences e.g. in BMI can not be excluded though it is intriguing that a lower BMI was found with CD and not with UC.
###end p 44
###begin p 45
###xml 10 14 10 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CNR1</italic>
###xml 57 61 57 61 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009453-Hoehe1">[34]</xref>
###xml 183 187 183 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009453-King1">[35]</xref>
###xml 316 320 316 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009453-Glas1">[36]</xref>
###xml 398 402 398 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CNR1</italic>
###xml 606 610 606 610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009453-Barmada1">[37]</xref>
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human CNR1 gene is localized on chromosome 6q14-q15. [34] Interestingly, an earlier genome-wide family-based linkage study found an association of this region with celiac disease [35]. We recently demonstrated that celiac disease and UC (but not CD) share another common susceptibility locus on chromosome 4q27. [36] Although none of the recent genome-wide association studies demonstrated the CNR1 gene as a major IBD susceptibility gene, a previous genome scan in 260 IBD-affected relative pairs found nominal evidence for linkage of IBD to loci on chromosome 6q (lod = 2.21 between D6S2436/D6S305). [37]
###end p 45
###begin p 46
###xml 108 112 108 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NOD2</italic>
###xml 114 118 114 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009453-Schnitzler1">[38]</xref>
###xml 120 124 120 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009453-Seiderer1">[39]</xref>
###xml 124 129 124 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL23R</italic>
###xml 131 135 131 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009453-Glas2">[40]</xref>
###xml 140 147 140 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATG16L1</italic>
###xml 147 151 147 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009453-Glas3">[41]</xref>
###xml 226 230 226 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009453-Glas4">[42]</xref>
###xml 410 414 410 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TLR4</italic>
###xml 462 466 462 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009453-Brand1">[43]</xref>
###xml 631 635 631 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009453-DeJager1">[44]</xref>
We recently confirmed a number of CD susceptibility genes found in genome-wide associations studies such as NOD2, [38], [39]IL23R, [40] and ATG16L1[41], but we also demonstrated differences in the genetic susceptibility to CD [42], suggesting that there are differences in the genetic susceptibility to IBD even between different Caucasian populations. In addition, other genetic associations such as those of TLR4 SNPs with CD susceptibility shown by our group [43] were not among the major CD susceptibility genes in a recent meta-analysis of genome-wide scans, although this gene has been confirmed as a CD susceptibility gene. [44]
###end p 46
###begin p 47
###xml 32 36 32 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CNR1</italic>
###xml 76 77 76 77 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 226 230 226 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009453-Jin1">[45]</xref>
###xml 261 265 261 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CNR1</italic>
###xml 355 359 355 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009453-Siegfried1">[46]</xref>
###xml 432 436 432 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CNR1</italic>
###xml 788 792 788 792 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009453-Gazzerro1">[47]</xref>
###xml 1017 1020 1017 1020 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1013 1020 1013 1020 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CNR1<sup>&#8722;/&#8722;</sup></italic>
###xml 1120 1123 1120 1123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009453-Massa1">[3]</xref>
###xml 605 613 <span type="species:ncbi:9606">patients</span>
###xml 809 817 <span type="species:ncbi:9606">patients</span>
###xml 1021 1025 <span type="species:ncbi:10090">mice</span>
###xml 1061 1065 <span type="species:ncbi:10090">mice</span>
###xml 1233 1241 <span type="species:ncbi:9606">patients</span>
Currently, it is unknown if the CNR1 1359 G/A (p.Thr453Thr) SNP modulates CB1 receptor expression or function. Particularly changes at amino acid positions 418-439 seem to be associated with a lack of receptor desensitization [45], and allelic variation in the CNR1 gene was suggested to be associated with a lower rather than a higher receptor activity, [46] but detailed studies investigating receptor activity based on different CNR1 genotypes are lacking. The assumption that allelic variation is associated with reduced CB1 activity would also explain the low BMI found in the 1359 A/A homozygous CD patients. Consistent with these data, the 1359 G/G wildtype genotype has been shown to be associated with an increased BMI and overweight in an Italian study of a healthy population. [47] A low BMI in CD patients is also considered to be an indicator of high disease activity. Therefore, 1359 A/A homozygosity could contribute to a more severe disease phenotype. This would be consistent with our results in CNR1-/- mice, demonstrating that these knockout mice take a more fulminate course in DNBS and DSS colitis. [3] However, functional experiments have to analyze if CNR1 signaling is indeed decreased in 1359 A/A homozygous patients.
###end p 47
###begin p 48
###xml 47 48 47 48 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 213 214 213 214 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 252 253 252 253 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 324 327 324 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009453-Massa1">[3]</xref>
###xml 329 332 329 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009453-Kimball1">[5]</xref>
###xml 360 361 360 361 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 566 567 566 567 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 769 770 769 770 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 905 908 905 908 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009453-Storr1">[7]</xref>
###xml 933 934 933 934 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 1028 1029 1028 1029 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 390 396 <span type="species:ncbi:10090">murine</span>
Our findings add evidence that targeting the CB1 receptor system may modulate intestinal inflammation, suggesting this receptor as a potential target for future treatments. Similarly, animal models suggest that CB1 receptor activation with exogenous CB1 receptor agonists induces protection against intestinal inflammation. [3], [5] Therefore, the increased CB1 receptor expression seen in murine colitis models is likely an intrinsic protective mechanism to counter-regulate the deleterious effects of intestinal inflammation. The physiological importance of the CB1 receptor and the endocannabinoid system becomes obvious when endocannabinoid levels are increased by blocking their degradation. Under these circumstances, intestinal inflammation is reduced and the CB1 receptor is involved in this protection, emphasizing the important pathophysiological role of this system in intestinal inflammation. [7] Whether monitoring of CB1 receptor function or genotyping can identify responders of future treatments targeting the CB1 receptor remains speculative and has to be clarified in clinical trials.
###end p 48
###begin p 49
###xml 36 40 36 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CNR1</italic>
###xml 188 196 <span type="species:ncbi:9606">patients</span>
In summary, we demonstrate that the CNR1 1359 G/A polymorphism modulates IBD susceptibility and phenotype. Specifically, we show that 1359 A/A homozygosity protects against UC and that CD patients carrying the minor A allele have a later disease onset and a lower BMI. These findings have to be confirmed in a larger replication study. Given the low prevalence of 1359 A/A homozygous carriers, this likely can be achieved only in a large multicenter trial. Nevertheless, our findings provide further evidence that endocannabinoids modulate intestinal inflammation, suggesting that this system could act as a target for future therapeutic interventions.
###end p 49
###begin title 50
References
###end title 50
###begin article-title 51
Marihuana as medicine. A plea for reconsideration.
###end article-title 51
###begin article-title 52
###xml 22 31 <span type="species:ncbi:3483">marijuana</span>
The future of medical marijuana.
###end article-title 52
###begin article-title 53
The endogenous cannabinoid system protects against colonic inflammation.
###end article-title 53
###begin article-title 54
Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation.
###end article-title 54
###begin article-title 55
Agonists of cannabinoid receptor 1 and 2 inhibit experimental colitis induced by oil of mustard and by dextran sulfate sodium.
###end article-title 55
###begin article-title 56
###xml 97 101 <span type="species:ncbi:10090">mice</span>
CB1 and TRPV1 receptors mediate protective effects on colonic electrophysiological properties in mice.
###end article-title 56
###begin article-title 57
###xml 102 103 102 103 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 110 111 110 111 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 79 83 <span type="species:ncbi:10090">mice</span>
Targeting endocannabinoid degradation protects against experimental colitis in mice: involvement of CB1 and CB2 receptors.
###end article-title 57
###begin article-title 58
Endocannabinoids and the Heart.
###end article-title 58
###begin article-title 59
###xml 53 56 <span type="species:ncbi:10116">rat</span>
Antagonism of the cannabinoid CB-1 receptor protects rat liver against ischemia-reperfusion injury complicated by endotoxemia.
###end article-title 59
###begin article-title 60
###xml 107 115 <span type="species:ncbi:9606">patients</span>
Altered pattern of cannabinoid type 1 receptor expression in adipose tissue of dysmetabolic and overweight patients.
###end article-title 60
###begin article-title 61
The endocannabinoid system: a promising target for the management of type 2 diabetes.
###end article-title 61
###begin article-title 62
Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors.
###end article-title 62
###begin article-title 63
Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells.
###end article-title 63
###begin article-title 64
CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis.
###end article-title 64
###begin article-title 65
The endocannabinoid system: a general view and latest additions.
###end article-title 65
###begin article-title 66
Perspectives of cannabinoids in gastroenterology.
###end article-title 66
###begin article-title 67
The role of the endocannabinoid system in the pathophysiology and treatment of irritable bowel syndrome.
###end article-title 67
###begin article-title 68
Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects.
###end article-title 68
###begin article-title 69
Cannabinoids for gastrointestinal diseases: potential therapeutic applications.
###end article-title 69
###begin article-title 70
Emerging Role of Cannabinoids in Gastrointestinal and Liver Diseases: Basic and Clinical Aspects.
###end article-title 70
###begin article-title 71
Evolving pathophysiologic models of functional gastrointestinal disorders.
###end article-title 71
###begin article-title 72
A role for inflammation in irritable bowel syndrome?
###end article-title 72
###begin article-title 73
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease.
###end article-title 73
###begin article-title 74
Activation of the cannabinoid 2 receptor (CB(2)) protects against experimental colitis.
###end article-title 74
###begin article-title 75
Association of a CB1 cannabinoid receptor gene (CNR1) polymorphism with severe alcohol dependence.
###end article-title 75
###begin article-title 76
CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia.
###end article-title 76
###begin article-title 77
A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998.
###end article-title 77
###begin article-title 78
Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology.
###end article-title 78
###begin article-title 79
###xml 50 55 <span type="species:ncbi:9606">human</span>
A frequent polymorphism in the coding exon of the human cannabinoid receptor (CNR1) gene.
###end article-title 79
###begin article-title 80
The role of fatty acid hydrolase (FAAH) gene variants in inflammatory bowel disease.
###end article-title 80
###begin article-title 81
###xml 62 67 <span type="species:ncbi:9606">women</span>
CB1 expression is attenuated in Fallopian tube and decidua of women with ectopic pregnancy.
###end article-title 81
###begin article-title 82
Schizophrenia and the cannabinoid receptor type 1 (CB1): association study using a single-base polymorphism in coding exon 1.
###end article-title 82
###begin article-title 83
Silent SNPs: impact on gene function and phenotype.
###end article-title 83
###begin article-title 84
###xml 36 41 <span type="species:ncbi:9606">human</span>
Genetic and physical mapping of the human cannabinoid receptor gene to chromosome 6q14-q15.
###end article-title 84
###begin article-title 85
A genome-wide family-based linkage study of coeliac disease.
###end article-title 85
###begin article-title 86
###xml 90 98 90 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL2/IL21</italic>
###xml 128 133 128 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL23R</italic>
Novel genetic risk markers for ulcerative colitis in the chromosome 4q27 region harboring IL2/IL21 region are in epistasis with IL23R and suggest a common genetic background for ulcerative colitis and celiac disease.
###end article-title 86
###begin article-title 87
A genome scan in 260 inflammatory bowel disease-affected relative pairs.
###end article-title 87
###begin article-title 88
###xml 69 75 69 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CARD15</italic>
###xml 88 96 <span type="species:ncbi:9606">patients</span>
Eight novel CARD15 variants detected by DNA sequence analysis of the CARD15 gene in 111 patients with inflammatory bowel disease.
###end article-title 88
###begin article-title 89
###xml 21 27 21 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CARD15</italic>
Homozygosity for the CARD15 frameshift mutation 1007fs is predictive of early onset of Crohn's disease with ileal stenosis, entero-enteral fistulas, and frequent need for surgical intervention with high risk of re-stenosis.
###end article-title 89
###begin article-title 90
###xml 41 46 41 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL23R</italic>
###xml 112 117 112 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL23R</italic>
###xml 119 125 119 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CARD15</italic>
###xml 131 138 131 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OCTN1/2</italic>
###xml 81 89 <span type="species:ncbi:9606">patients</span>
rs1004819 is the main disease-associated IL23R variant in German Crohn's disease patients: combined analysis of IL23R, CARD15, and OCTN1/2 variants.
###end article-title 90
###begin article-title 91
###xml 4 11 4 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATG16L1</italic>
The ATG16L1 gene variants rs2241879 and rs2241880 (T300A) are strongly associated with susceptibility to Crohn's disease in the German population.
###end article-title 91
###begin article-title 92
rs224136 on chromosome 10q21.1 and variants in PHOX2B, NCF4, and FAM92B are not major genetic risk factors for susceptibility to Crohn's disease in the German population.
###end article-title 92
###begin article-title 93
###xml 75 86 75 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CARD15/NOD2</italic>
The role of Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms and CARD15/NOD2 mutations in the susceptibility and phenotype of Crohn's disease.
###end article-title 93
###begin article-title 94
The role of the Toll receptor pathway in susceptibility to inflammatory bowel diseases.
###end article-title 94
###begin article-title 95
Distinct domains of the CB1 cannabinoid receptor mediate desensitization and internalization.
###end article-title 95
###begin article-title 96
###xml 48 52 48 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CNR1</italic>
Association study of cannabinoid receptor gene (CNR1) alleles and anorexia nervosa: differences between restricting and binging/purging subtypes.
###end article-title 96
###begin article-title 97
Association between cannabinoid type-1 receptor polymorphism and body mass index in a southern Italian population.
###end article-title 97
###begin p 98
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 98
###begin p 99
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: M. Storr is supported by grants from the Deutsche Forschungsgemeinschaft (DFG STO645/2-2), the Crohn's and Colitis Foundation of Canada (CCFC), and a grant from the University of Calgary (URGC-1011592). J. Diegelmann received a grant from the University of Munich (Promotionsstipendium). S. Brand is supported by grants from the DFG (BR 1912/5-1), the Else Kraner-Fresenius-Stiftung (Else Kraner Fresenius Memorial Stipendium 2005; P50/05/EKMS05/62), by the Ludwig-Demling Grant 2007 from DCCV e.V., and grants from the Ludwig-Maximilians University Munich (Excellence Initiative - Investment Fund 2008 and FaFoLe program). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 99

